



Recent Advances in Antimicrobial Drug Development to Combat Antimicrobial Resistance

Sharad G. Funde^{1,2}, Sharad T Gavhane³, Utkarsh B. Funde³

¹ Dept. of Biochemistry, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajnagar, Maharashtra, India

²Dept. of Microbiology, Government Arts & Science College Chhatrapati Sambhajnagar, Maharashtra, India

³Department of Medicine, Symbiosis Medical and Research Hospital Pune, Maharashtra, India

Abstract

Antimicrobial resistance (AMR) has emerged as one of the most serious global public health challenges, threatening the effective prevention and treatment of infectious diseases. The widespread misuse and overuse of antimicrobial agents in human medicine, agriculture, and animal husbandry have accelerated the development of resistant pathogens, rendering many conventional antibiotics ineffective. As a result, there is an urgent need for the development of new and innovative antimicrobial therapies to address this growing crisis.

This review highlights recent advances in antimicrobial drug development aimed at combating resistance. Novel antibiotics with unique mechanisms of action, along with improved derivatives of existing drugs, have shown promise against multidrug-resistant pathogens. Emerging approaches such as antimicrobial peptides, bacteriophage therapy, nanotechnology-based delivery systems, and CRISPR-Cas gene-editing technologies offer innovative alternatives to traditional treatments. Additionally, strategies like drug repurposing, combination therapy, and the application of artificial intelligence (AI) have accelerated the identification and optimization of potential antimicrobial agents.

Despite these advancements, several challenges persist, including resistance evolution, safety concerns, limited clinical data, and issues related to accessibility and affordability. Addressing these barriers requires sustained research efforts, supportive regulatory frameworks, and global collaboration. Significant progress has been made, combating AMR demands a multifaceted approach that integrates scientific innovation, responsible antimicrobial use, and international cooperation. Future research should focus on developing effective, safe, and accessible therapies to ensure long-term control of AMR and the continued success of modern medicine.

Keywords - Antimicrobial resistance, Drug development, AMR, Novel antibiotics, Antimicrobial peptides, Nanotechnology

1 Introduction -

1.1 Overview of Infectious Diseases and Global Burden

Infectious diseases remain one of the leading causes of morbidity and mortality worldwide, posing a significant threat to global public health. Despite substantial progress in medical science, the burden of infectious diseases continues to be disproportionately high in low and middle-income countries due to inadequate healthcare infrastructure, poor sanitation, and limited access to effective treatments. Diseases caused by bacteria, viruses, fungi, and parasites contribute to millions of deaths annually, with respiratory infections, diarrheal diseases, tuberculosis, and malaria among the most prevalent.¹ The emergence of new

infectious pathogens and the re-emergence of previously controlled diseases have further complicated disease management. Globalization, increased travel, urbanization, and climate change have accelerated the spread of infectious agents across geographical boundaries.³ In addition, hospital-acquired infections have become a major concern, particularly in intensive care units, where immunocompromised patients are highly susceptible.

The economic burden associated with infectious diseases is also substantial, including healthcare costs, productivity loss, and long-term disability. The ongoing challenge of managing infectious diseases highlights the critical importance of effective antimicrobial agents. However, the growing threat of AMR is undermining decades of progress in infection control and treatment.

1.2 Definition and Significance of AMR

AMR refers to the ability of microorganisms such as bacteria, viruses, fungi, and parasites to survive and proliferate despite exposure to antimicrobial agents that were previously effective in inhibiting or killing them.² This phenomenon renders standard treatments ineffective, leading to persistent infections and increased risk of spread to others. AMR is recognized as one of the most pressing global health challenges of the 21st century.⁴ It compromises the effectiveness of essential medical procedures, including surgeries, chemotherapy, organ transplantation, and intensive care, all of which rely heavily on the availability of effective antimicrobial agents to prevent and treat infections. Without effective antibiotics, even minor infections can become life-threatening.

The significance of AMR extends beyond human health, affecting veterinary medicine, agriculture, and the environment.⁵ The transmission of resistant pathogens between humans, animals, and ecosystems reflects the interconnected nature of AMR, often described under the “One Health” approach. International organizations have warned that if current trends continue, AMR could lead to millions of deaths annually by 2050 and impose a severe economic burden globally.

1.3 Causes of Resistance (Overuse, Misuse, Genetic Mutations) -

The development and spread of AMR are driven by a combination of biological, clinical, and societal factors.² One of the primary causes is the overuse of antimicrobial agents. Antibiotics are frequently prescribed unnecessarily for viral infections, against which they are ineffective.⁶ This inappropriate usage creates selective pressure that encourages the survival and proliferation of resistant strains. Misuse of antibiotics is another critical factor contributing to resistance. Patients often fail to complete prescribed treatment courses, leading to partial elimination of pathogens and the survival of resistant organisms. Self-medication, easy availability of over-the-counter antibiotics in many regions, and lack of awareness further exacerbate the problem.

In human-related factors, antimicrobial use in agriculture and animal husbandry significantly contributes to the development of resistance. Antibiotics are commonly used for growth promotion and disease prevention in livestock, leading to the emergence of resistant bacteria that can be transmitted to humans through food and environmental pathways.⁷ At the molecular level, genetic mutations play a crucial role in resistance development. Spontaneous mutations in microbial genomes can alter drug targets, reduce drug uptake, or enhance efflux mechanisms. Horizontal gene transfer mechanisms such as transformation, transduction, and conjugation enable the rapid spread of resistance genes among microbial populations. Mobile genetic elements like plasmids and transposons facilitate the dissemination of resistance traits across different species, accelerating the global spread of AMR.²

1.4 Limitations of Existing Antibiotics -

Though antibiotics have revolutionized modern medicine, their effectiveness is increasingly limited by the rapid emergence of resistant pathogens. Many existing antibiotics target a narrow range of bacterial processes, such as cell wall synthesis, protein synthesis, and DNA replication. Over time, bacteria have evolved mechanisms to evade these actions, reducing the efficacy of these drugs. Another significant limitation is the lack of novel antibiotic classes introduced in recent decades. Most newly developed antibiotics are modifications of existing drug classes, which often leads to cross-resistance. As a result,

multidrug-resistant (MDR), extensively drug-resistant, and pan-drug-resistant strains have emerged, posing serious therapeutic challenges.

Antibiotics often exhibit non-specific activity, affecting not only pathogenic bacteria but also beneficial microbiota.⁸ This disruption of the normal microbial flora can lead to secondary infections and other health complications. Toxicity and adverse side effects further limit the clinical use of certain antibiotics. Pharmacokinetic and pharmacodynamic challenges, such as poor tissue penetration and rapid drug degradation, also affect the effectiveness of existing antibiotics.⁹ Moreover, the development of bacterial biofilms significantly reduces antibiotic susceptibility, as biofilm-associated bacteria are protected by a matrix that limits drug penetration and enhances resistance.

1.5 Need for Innovative Drug Discovery Strategies -

Given the escalating threat of AMR and the limitations of existing therapies, there is an urgent need for innovative approaches to antimicrobial drug discovery and development.¹⁰ Traditional methods of antibiotic discovery, primarily based on natural product screening, have reached a plateau, necessitating the exploration of alternative strategies. Recent advances in molecular biology, genomics, and bioinformatics have opened new avenues for identifying novel drug targets and designing effective antimicrobial agents.¹¹ Target-based drug discovery, high-throughput screening, and structure-based drug design are being increasingly utilized to develop next-generation therapeutics.¹¹

Innovative strategies include the development of antimicrobial peptides, bacteriophage therapy, and nanotechnology-based drug delivery systems.¹² These approaches offer advantages such as enhanced specificity, reduced toxicity, and the ability to overcome conventional resistance mechanisms. CRISPR-Cas systems have emerged as a promising tool for selectively targeting and eliminating resistance genes in microbial populations.¹³ Drug repurposing and combination therapy are also gaining attention as cost-effective and time-efficient approaches to combat resistance. By combining existing drugs or identifying new uses for approved compounds, it is possible to enhance antimicrobial efficacy and reduce the likelihood of resistance development. The integration of AI and machine learning in drug discovery has significantly accelerated the identification of potential antimicrobial compounds.¹⁴ These technologies enable the analysis of large datasets to predict drug-target interactions and optimize lead compounds.¹⁴ Addressing the global challenge of AMR requires a multifaceted approach that combines scientific innovation, policy interventions, and global collaboration. The development of novel antimicrobial agents, along with responsible usage and effective stewardship programs, is essential to safeguard the effectiveness of antimicrobial therapies for future generations.

2 Mechanisms of AMR -

AMR arises through diverse and complex mechanisms that enable microorganisms to survive exposure to antimicrobial agents. These mechanisms may be intrinsic or acquired and often act synergistically, making treatment increasingly difficult. Understanding these resistance strategies is crucial for the development of novel therapeutic interventions. The major mechanisms of AMR include enzymatic degradation, target modification, efflux pumps, reduced permeability, biofilm formation, and horizontal gene transfer.¹⁵

2.1 Enzymatic Degradation (e.g., β -lactamases) -

One of the most common and effective mechanisms of AMR is the enzymatic degradation or inactivation of drugs by microbial enzymes. Bacteria produce specific enzymes capable of chemically modifying or destroying antibiotics before they reach their target sites. A classic example is the production of β -lactamases, enzymes that hydrolyze the β -lactam ring present in antibiotics such as penicillins, cephalosporins, and carbapenems.¹⁶ This hydrolysis renders the antibiotic molecule inactive, thereby preventing it from inhibiting bacterial cell wall synthesis. Over time, bacteria have evolved a wide variety of β -lactamases, including extended-spectrum β -lactamases and carbapenemases, which can degrade even the most potent β -lactam antibiotics.¹⁶

β -lactamases and other enzymes such as aminoglycoside-modifying enzymes (acetyltransferases, phosphotransferases, and nucleotidyltransferases) alter antibiotic molecules through chemical modifications. These changes reduce the binding affinity of the drug to its target, effectively neutralizing its antimicrobial

activity.¹⁷ The genes encoding these enzymes are often located on plasmids or transposons, facilitating their rapid spread among bacterial populations. The widespread dissemination of enzyme-mediated resistance poses a major challenge in clinical settings, particularly in the treatment of hospital-acquired infections.

2.2 Target Modification

Target modification is another critical mechanism by which microorganisms evade the action of antimicrobial agents. Antibiotics typically function by binding to specific cellular targets such as enzymes, ribosomes, or structural components. Alterations in these targets can reduce or eliminate drug binding, thereby conferring resistance. One well-known example is the modification of penicillin-binding proteins (PBPs) in bacteria, which reduces the effectiveness of β -lactam antibiotics.¹⁸ Methicillin-resistant *Staphylococcus aureus* (MRSA) produces an altered PBP (PBP2a) with low affinity for β -lactam drugs, allowing the bacteria to continue synthesizing its cell wall even in the presence of antibiotics.¹⁹ Similarly, resistance to macrolides, lincosamides, and streptogramins often involves methylation of ribosomal RNA, which prevents antibiotic binding to the bacterial ribosome.²⁰ Mutations in genes encoding DNA gyrase and topoisomerase IV can also confer resistance to fluoroquinolones.²¹ Target modification can occur through spontaneous mutations or through the acquisition of resistance genes. These changes are highly specific and often do not significantly affect the normal function of the bacterial cell, making them a highly efficient resistance strategy.

2.3 Efflux Pumps -

Efflux pumps are membrane-bound transport proteins that actively expel antimicrobial agents from the bacterial cell, thereby reducing intracellular drug concentrations to sub-lethal levels. These pumps play a significant role in both intrinsic and acquired resistance. Efflux systems can be specific for a single antibiotic or capable of transporting a wide range of structurally unrelated compounds, contributing to multidrug resistance (MDR).²² Major families of efflux pumps include the ATP-binding cassette transporters, the major facilitator superfamily, the resistance-nodulation-division family, and the multidrug and toxic compound extrusion family.²³ For example, the AcrAB-TolC efflux system in Gram-negative bacteria is well known for its ability to expel multiple classes of antibiotics, including tetracyclines, fluoroquinolones, and β -lactams.^{22,23} Overexpression of efflux pumps can significantly decrease antibiotic susceptibility and is often associated with resistance in clinical isolates. Efflux-mediated resistance can also work in conjunction with other mechanisms, such as reduced permeability, to enhance the overall resistance phenotype. Inhibiting efflux pumps is therefore considered a promising strategy for restoring antibiotic efficacy.²⁴

2.4 Reduced Permeability -

Reduced permeability is another important mechanism of AMR, particularly in Gram-negative bacteria.²² The outer membrane of these bacteria acts as a barrier that limits the entry of antibiotics into the cell. Antibiotics typically enter bacterial cells through porin channels—protein structures that allow the passive diffusion of small molecules. Alterations in porin structure, reduced expression of porins, or complete loss of these channels can significantly decrease antibiotic uptake. For instance, resistance to β -lactam antibiotics and carbapenems in Gram-negative bacteria is often associated with the loss or modification of porin proteins such as OmpF and OmpC.²⁵ This reduced permeability limits drug access to intracellular targets, thereby decreasing antibiotic effectiveness.²⁵ Additionally, changes in membrane lipid composition can also affect drug permeability. The combination of reduced permeability and active efflux further enhances resistance, making it difficult to achieve therapeutic drug concentrations within the bacterial cell.^{22,23,24,25}

2.5 Biofilm Formation -

Biofilm formation is a complex and highly protective mode of growth that significantly contributes to AMR. Biofilms are structured communities of microorganisms embedded in a self-produced extracellular polymeric matrix composed of polysaccharides, proteins, and nucleic acids. Within biofilms, bacteria exhibit reduced metabolic activity and increased tolerance to antimicrobial agents.²⁶ The extracellular matrix acts as a physical barrier, limiting the penetration of antibiotics. Moreover, the presence of persister cells—dormant variants of bacteria—further enhances resistance, as these cells are highly tolerant to antibiotics. Biofilms are commonly associated with chronic infections, such as those involving medical devices (catheters, implants),

respiratory tract infections, and wound infections. The resistance exhibited by biofilm-associated bacteria can be up to 1000 times greater than that of planktonic (free-living) cells.²⁷ Biofilm formation physical protection, biofilms facilitate the exchange of genetic material, including resistance genes, among microbial cells. This environment promotes the persistence and spread of resistant strains, posing significant challenges for treatment.

2.6 Horizontal Gene Transfer -

Horizontal gene transfer (HGT) is a major driver of the rapid spread of AMR among bacterial populations. Unlike vertical gene transfer (inheritance from parent to offspring), HGT allows bacteria to acquire genetic material from other organisms, even across different species. There are three primary mechanisms of HGT: transformation, transduction, and conjugation. Transformation involves the uptake of free DNA from the environment. Transduction is mediated by bacteriophages, which transfer genetic material between bacteria.²⁸ Conjugation involves the direct transfer of plasmids through cell-to-cell contact via a conjugative pilus. Plasmids, transposons, and integrons play a crucial role in the dissemination of resistance genes.²⁸ These mobile genetic elements often carry multiple resistance determinants, enabling the simultaneous spread of resistance to different classes of antibiotics. HGT is particularly significant in environments with high antibiotic exposure, such as hospitals and agricultural settings, where selective pressure promotes the survival and proliferation of resistant strains.²⁹ The rapid global spread of resistance genes, such as those encoding carbapenemases and colistin resistance, highlights the critical role of HGT in the AMR crisis.

3 Traditional Antibiotic Development: Challenges and Emergence of MDR Strains -

The development of antibiotics has historically been one of the most significant achievements in modern medicine, transforming once-lethal infections into manageable conditions. However, traditional antibiotic development now faces critical challenges that limit its effectiveness in combating the rapidly evolving threat of AMR.²² One of the primary issues is the slow pace of discovery and development of new antibiotics compared to the rapid emergence of resistant pathogens.^{22,23} The conventional pipeline, which involves target identification, compound screening, preclinical studies, and clinical trials, is both time-consuming and costly, often taking more than a decade for a drug to reach the market.

A major concern within this context is the emergence and spread of MDR strains. MDR microorganisms are defined as pathogens that exhibit resistance to at least one agent in three or more antimicrobial classes.²⁶ These strains have become increasingly prevalent in both community and hospital settings, significantly complicating treatment options. Notable examples include MRSA, MDR *Mycobacterium tuberculosis*, and resistant strains of *Escherichia coli* and *Klebsiella pneumoniae*.^{29,26,30} These pathogens are associated with higher morbidity, mortality, prolonged hospital stays, and increased healthcare costs. The rise of MDR strains is largely driven by selective pressure exerted through the widespread and often inappropriate use of antibiotics. In traditional drug development, many antibiotics are derivatives or modifications of existing classes, which limits their ability to overcome existing resistance mechanisms. As a result, cross-resistance frequently occurs, reducing the long-term efficacy of newly introduced drugs. Furthermore, pharmaceutical companies often face limited financial incentives to invest in antibiotic development due to lower profitability compared to drugs for chronic conditions, leading to a decline in the antibiotic pipeline.^{27,29}

Another challenge is the ability of bacteria to rapidly adapt through genetic mutations and horizontal gene transfer.²⁸ Resistance genes can spread quickly within and between bacterial populations via plasmids, transposons, and integrons. This genetic flexibility allows pathogens to develop resistance even to newly introduced antibiotics within a short period.²⁹ Additionally, biofilm formation further complicates treatment, as bacteria within biofilms exhibit enhanced resistance to antimicrobial agents and host immune responses. Overall, the emergence of MDR strains highlights the limitations of traditional antibiotic development strategies and underscores the urgent need for innovative approaches. Without significant advancements in drug discovery and a global effort to promote responsible antibiotic use, the effectiveness of existing treatments will continue to decline, posing a serious threat to public health worldwide.

4 Recent Advances in Antimicrobial Drug Development -

The alarming rise of AMR has accelerated the search for innovative therapeutic strategies beyond traditional antibiotics. Recent advances in antimicrobial drug development focus on novel mechanisms of action, targeted therapies, and interdisciplinary approaches to effectively combat resistant pathogens.

4.1 Novel Antibiotics -

The development of novel antibiotics remains a critical strategy in addressing resistance.¹⁴ In recent years, researchers have focused on discovering new classes of antibiotics with unique mechanisms of action to circumvent existing resistance pathways.²⁵ These include agents targeting bacterial membrane integrity, novel protein synthesis pathways, and previously unexplored metabolic processes. New classes, significant progress has been made in modifying existing antibiotics to enhance their efficacy and overcome resistance. Structural modifications improve drug stability, bioavailability, and binding affinity to bacterial targets.¹¹ Such semi-synthetic derivatives often exhibit broader activity against resistant strains. Examples of successful advancements include oxazolidinones, which inhibit protein synthesis by binding to the bacterial ribosome, and lipopeptides, which disrupt bacterial cell membrane function.³¹ These drugs are particularly effective against Gram-positive MDR pathogens. However, the emergence of resistance even to these advanced agents highlights the need for continuous innovation.

4.2 Antimicrobial Peptides (AMPs)

Antimicrobial peptides are short, naturally occurring molecules that form a crucial part of the innate immune system in various organisms. They exhibit broad-spectrum activity against bacteria, fungi, viruses, and even some parasites.³² The primary mechanism of action of AMPs involves disruption of microbial cell membranes. Due to their amphipathic nature, AMPs interact with lipid bilayers, leading to pore formation, membrane destabilization, and eventual cell death. Some AMPs also interfere with intracellular processes such as protein and nucleic acid synthesis. AMPs offer several advantages over conventional antibiotics, killing, a lower likelihood of resistance development, and broad-spectrum activity.³³ Their ability to target multiple cellular components reduces the chances of microbial adaptation. Despite their promise, clinical translation of AMPs faces challenges such as toxicity, susceptibility to proteolytic degradation, and high production costs. However, ongoing research is focused on designing synthetic and modified peptides with improved stability and reduced toxicity. Several AMPs are currently undergoing clinical trials, indicating their potential as next-generation antimicrobials.³²

4.3 Phage Therapy

Phage therapy utilizes bacteriophages, viruses that specifically infect and kill bacteria, as therapeutic agents.³⁴ This approach has gained renewed interest as an alternative to antibiotics, especially for treating MDR infections.³⁴ Bacteriophages function by attaching to specific receptors on bacterial cells, injecting their genetic material, and replicating within the host. This leads to bacterial lysis and release of new phage particles that can infect neighboring bacteria. This self-amplifying mechanism enhances therapeutic effectiveness.

One of the major advantages of phage therapy is its high specificity. Phages target specific bacterial species without affecting beneficial microbiota, reducing the risk of dysbiosis.³⁵ Additionally, phages can evolve alongside bacteria, potentially overcoming resistance. Clinical applications of phage therapy have shown promising results in treating chronic infections, including wound infections and antibiotic-resistant bacterial diseases. Case studies have demonstrated successful treatment of infections unresponsive to conventional antibiotics. However, challenges such as regulatory approval, standardization, and potential immune responses remain barriers to widespread adoption.

4.4 Nanotechnology-Based Antimicrobials -

Nanotechnology has emerged as a powerful tool in antimicrobial drug development, offering innovative solutions for overcoming resistance and improving drug delivery.³⁶ Nanoparticles such as silver, gold, and zinc oxide exhibit intrinsic antimicrobial properties.

These nanoparticles act through multiple mechanisms, including generation of reactive oxygen species (ROS), disruption of microbial membranes, and interference with cellular functions.³⁷ Their small size allows for enhanced interaction with microbial cells, increasing their antimicrobial efficacy. Nanotechnology also plays a crucial role in drug delivery systems. Nanocarriers such as liposomes, polymeric nanoparticles, and dendrimers enable targeted delivery of antimicrobial agents, improving drug concentration at the infection site while minimizing systemic toxicity.³⁸ This targeted approach enhances therapeutic outcomes and reduces side effects. Moreover, nanotechnology-based systems can be engineered to provide controlled and sustained drug release, improving treatment efficiency. These advantages, concerns regarding toxicity, environmental impact, and long-term safety must be addressed before large-scale clinical application.

4.5 CRISPR-Cas Systems in Antimicrobial Therapy -

CRISPR-Cas systems represent a groundbreaking approach in antimicrobial therapy by enabling precise genetic targeting of resistant bacteria.³⁹ Originally discovered as a bacterial immune system, CRISPR-Cas technology can be engineered to selectively target and disrupt resistance genes in pathogens.³⁹ This gene-editing approach allows for the elimination of specific resistance determinants without affecting non-target bacteria. By targeting plasmids or chromosomal resistance genes, CRISPR-based systems can restore bacterial susceptibility to antibiotics.⁴⁰ The precision of CRISPR-Cas systems offers significant advantages over conventional therapies, including reduced off-target effects and the ability to specifically target pathogenic strains. Delivery systems such as bacteriophages and nanoparticles are being explored to efficiently introduce CRISPR components into bacterial cells.⁴¹ However, challenges such as delivery efficiency, potential off-target effects, and ethical concerns related to genetic manipulation must be carefully addressed. Regulatory frameworks and safety assessments are essential for the successful implementation of this technology in clinical settings.

4.6 Anti-biofilm Strategies

Biofilms are structured microbial communities embedded in a protective extracellular matrix, which significantly enhances resistance to antimicrobial agents.²⁶ Targeting biofilms has become a key focus in recent antimicrobial strategies.²⁷ Biofilm disruption agents aim to degrade the extracellular matrix, exposing bacteria to antimicrobial agents.^{26,27} Enzymes such as DNAases and proteases are being investigated for their ability to break down biofilm structures.⁴² Quorum sensing inhibitors represent another promising approach. By interfering with bacterial communication systems, these agents prevent the coordination required for biofilm formation and maintenance. This reduces virulence and enhances susceptibility to antibiotics. Surface modifications of medical devices, such as coating with antimicrobial agents or anti-adhesive materials, help prevent biofilm formation.⁴³ These strategies are particularly important in reducing hospital-acquired infections associated with implants and catheters.

4.7 Host-Directed Therapies

Host-directed therapies (HDTs) focus on enhancing the host's immune response rather than directly targeting pathogens.⁴⁴ This approach reduces selective pressure on microbes, thereby limiting the development of resistance. These therapies include immunomodulators that boost innate and adaptive immune responses, enabling the host to effectively clear infections. Strategies such as cytokine therapy, vaccination, and modulation of immune signaling pathways are being explored.⁴⁵ HDTs aim to reduce pathogen virulence by targeting host factors required for infection. This indirect approach weakens the pathogen's ability to survive and replicate within the host. The use of immunomodulators offers advantages such as broad applicability and reduced likelihood of resistance. However, challenges include variability in patient immune responses and the risk of immune overactivation.

5 Drug Repurposing and Combination Therapy -

The growing threat of AMR and the slow pace of novel antibiotic discovery have prompted increased interest in alternative strategies such as drug repurposing and combination therapy.⁴⁶ These approaches offer practical, cost-effective, and time-efficient solutions to enhance antimicrobial efficacy and combat resistant pathogens. Drug repurposing, also known as drug repositioning, involves the use of existing approved or investigational drugs for new antimicrobial purposes.⁴⁶ Since these drugs have already undergone extensive

safety and pharmacokinetic evaluations, their development timeline is significantly shorter compared to novel drug discovery.⁴⁷ This approach reduces the cost and risk associated with early-stage drug development while providing a rapid response to emerging resistant infections.

Several non-antibiotic drugs have demonstrated promising antimicrobial activity. For instance, certain anticancer agents, antifungal drugs, and anti-inflammatory compounds have been found to possess antibacterial properties or enhance the activity of existing antibiotics.⁴⁸ Drugs such as metformin, statins, and some antipsychotics have shown the ability to disrupt bacterial metabolism, inhibit biofilm formation, or alter host-pathogen interactions.⁴⁹ Repurposed drugs can act through novel mechanisms that differ from conventional antibiotics, thereby reducing the likelihood of cross-resistance. In addition to repurposing, combination therapy has emerged as a powerful strategy to improve treatment outcomes. This approach involves the simultaneous use of two or more antimicrobial agents with complementary mechanisms of action. Synergistic drug combinations enhance bacterial killing by targeting multiple cellular pathways, thereby increasing therapeutic efficacy. For example, the combination of β -lactam antibiotics with β -lactamase inhibitors helps overcome resistance mediated by enzyme degradation. Similarly, combining antibiotics that target cell wall synthesis with those that inhibit protein synthesis can produce enhanced antimicrobial effects.

One of the key advantages of combination therapy is its ability to reduce the development of resistance. By exposing pathogens to multiple agents simultaneously, the probability of bacteria acquiring mutations that confer resistance to all drugs in the combination is significantly reduced. This multi-target approach creates a higher barrier for resistance evolution and can prolong the clinical usefulness of existing antibiotics.

Combination therapy is particularly effective in treating infections caused by MDR organisms, where single-drug treatments often fail.⁵⁰ It is widely used in the management of diseases such as tuberculosis, HIV-associated infections, and severe hospital-acquired infections. Combining antibiotics with non-antibiotic adjuvants, such as efflux pump inhibitors or biofilm-disrupting agents, can further enhance antimicrobial activity.^{26,27} Despite its advantages, combination therapy also presents certain challenges. Potential drug-drug interactions, increased risk of toxicity, and the complexity of optimizing dosage regimens must be carefully considered. Inappropriate use of combinations may contribute to resistance if not properly managed. Drug repurposing and combination therapy represent promising strategies in the fight against AMR. By maximizing the utility of existing drugs and enhancing their effectiveness through synergistic interactions, these approaches provide valuable tools to address the urgent need for effective antimicrobial treatments while minimizing the emergence and spread of resistance.

6 Role of Artificial Intelligence in Drug Discovery

The integration of AI into antimicrobial drug discovery has revolutionized the way new therapeutics are identified and developed.¹⁴ In the face of escalating AMR and the limitations of traditional drug discovery methods, AI offers innovative, data-driven solutions that enhance efficiency, accuracy, and speed.¹⁴ By leveraging machine learning algorithms, big data analytics, and computational modeling, AI is transforming the identification of novel antimicrobial agents and optimizing the overall drug development pipeline.⁵¹ One of the most significant contributions of AI lies in identifying novel compounds with antimicrobial activity. Traditional methods of drug discovery rely heavily on trial-and-error screening of large chemical libraries, which is time-consuming and resource-intensive. AI-driven approaches, however, can analyze vast datasets of chemical structures and biological activities to predict potential drug candidates.⁵¹ Machine learning models are trained on existing data to recognize patterns and relationships between molecular structures and their antimicrobial properties. This enables the rapid identification of new compounds with desired characteristics, including activity against MDR pathogens. AI has been successfully used to discover entirely new classes of antibiotics by exploring previously uncharted chemical spaces.

In discovering new compounds, AI plays a crucial role in predictive modeling for AMR. Resistance development is a dynamic and complex process influenced by genetic mutations, microbial adaptation, and environmental factors. AI algorithms can analyze genomic data, mutation patterns, and clinical datasets to predict how bacteria may evolve resistance to specific drugs. These predictive models help researchers

design drugs that are less susceptible to resistance mechanisms.¹⁴ AI can identify resistance genes and track their spread across populations, aiding in surveillance and early intervention strategies.⁵² This proactive approach allows scientists to stay ahead of evolving pathogens and develop more robust antimicrobial therapies. Another important application of AI is in accelerating drug screening processes. High-throughput screening of chemical compounds is a critical step in drug discovery, but it is often slow and costly when performed using conventional laboratory methods. AI enhances this process by prioritizing the most promising candidates for experimental validation.¹⁴ Virtual screening techniques, powered by AI, simulate interactions between drug molecules and biological targets, significantly reducing the number of compounds that need to be physically tested.^{14,52} This not only speeds up the discovery process but also reduces costs and resource utilization. AI facilitates structure-based drug design by predicting how molecules bind to specific targets, enabling the optimization of lead compounds.⁵¹ Deep learning models can generate new molecular structures with improved efficacy, stability, and safety profiles. Integration of AI with robotics and automation further streamlines laboratory workflows, allowing for rapid iteration and refinement of drug candidates. Its immense potential, the application of AI in antimicrobial drug discovery faces certain challenges. The quality and availability of data are critical for training accurate models, and biases in datasets can affect outcomes. The interpretability of AI models remains a concern, as complex algorithms may function as “black boxes.” Regulatory acceptance and integration into existing drug development frameworks also require careful consideration.

7 Clinical Trials and Regulatory Perspectives -

The successful translation of antimicrobial discoveries into clinically effective therapies depends heavily on well-structured clinical trials and supportive regulatory frameworks. In the context of rising AMR, there is an urgent need to accelerate the development and approval of new antimicrobial agents while ensuring their safety, efficacy, and accessibility.

7.1 Current Pipeline Drugs in Clinical Trials -

The global antimicrobial pipeline has shown gradual improvement in recent years, with several novel agents and modified antibiotics advancing through different phases of clinical trials. These include drugs targeting MDR Gram-negative bacteria, such as β -lactam/ β -lactamase inhibitor combinations, siderophore cephalosporins, and next-generation tetracyclines.⁵³ New oxazolidinone derivatives and antimicrobial peptides are being evaluated for their effectiveness against resistant Gram-positive pathogens. Several non-traditional therapies are also entering clinical evaluation, including bacteriophage-based treatments, monoclonal antibodies, and microbiome-modulating therapies.⁵³ These innovative approaches aim to complement or replace conventional antibiotics, particularly in cases where resistance has rendered standard treatments ineffective. Despite these advancements, the number of truly novel antibiotic classes in late-stage clinical trials remains limited, highlighting the need for sustained research and investment. Clinical trials for antimicrobial agents face unique challenges, such as difficulty in patient recruitment, variability in infection types, and ethical concerns in placebo-controlled studies.⁵⁴ Moreover, demonstrating superiority over existing treatments can be complex, especially when current therapies still provide partial effectiveness.

7.2 Regulatory Challenges and Approvals

Regulatory approval is a critical step in bringing new antimicrobial agents to market. However, the process is often lengthy and complex, involving stringent requirements for demonstrating safety, efficacy, and quality. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have introduced streamlined pathways, such as the Qualified Infectious Disease Product (QIDP) designation and accelerated approval programs, to encourage antimicrobial development.⁵⁵ Despite these efforts, several challenges persist. The high cost of clinical trials, combined with limited financial returns, discourages pharmaceutical companies from investing in antibiotic research. Unlike drugs for chronic diseases, antibiotics are typically used for short durations, resulting in lower profitability. Regulatory requirements for large-scale clinical trials can be difficult to meet, particularly for rare or highly resistant infections.⁵⁶ Another challenge is balancing rapid approval with patient safety. While expedited

pathways can bring life-saving drugs to market more quickly, insufficient data on long-term safety and resistance development may pose risks. Therefore, post-marketing surveillance and pharmacovigilance are essential components of the regulatory process.

7.3 Global Initiatives (e.g., WHO, CDC Programs)

To address the global threat of AMR, several international organizations and initiatives have been established to support antimicrobial research, surveillance, and stewardship. The World Health Organization plays a central role in coordinating global efforts through its Global Action Plan on AMR, which emphasizes improving awareness, strengthening surveillance, reducing infection incidence, and promoting sustainable investment in new medicines.⁵⁷ Similarly, the Centers for Disease Control and Prevention has implemented programs such as the Antibiotic Resistance Solutions Initiative, which focuses on tracking resistant infections, improving antibiotic use, and supporting outbreak response.⁵⁸ These programs aim to reduce the spread of resistance and enhance the development of effective treatments. Other global partnerships, such as the Global Antibiotic Research and Development Partnership (GARDP) and CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), provide funding and support for early-stage research and clinical development of new antimicrobial agents.⁵⁹ These collaborative efforts are essential for bridging the gap between scientific discovery and clinical application.

8 Challenges and Limitations in Antimicrobial Drug Development

Despite significant progress in antimicrobial drug discovery, numerous challenges and limitations continue to hinder the effective management of AMR. These obstacles span biological, clinical, economic, and societal domains, ultimately impacting the successful development, approval, and accessibility of new therapies.

8.1 Resistance Evolution

One of the most critical challenges in antimicrobial drug development is the continuous evolution of resistance among microorganisms. Bacteria possess remarkable genetic adaptability, allowing them to rapidly develop mechanisms to evade newly introduced drugs.²² Even when novel antibiotics are designed to target specific pathways, selective pressure exerted by their use can lead to the emergence of resistant strains over time.⁶⁰ Resistance evolution occurs through multiple mechanisms, including spontaneous genetic mutations and horizontal gene transfer via plasmids, transposons, and integrons.²⁸ These processes enable bacteria to acquire and disseminate resistance genes not only within the same species but also across different genera. As a result, resistance can spread rapidly within communities and healthcare settings. The misuse and overuse of antibiotics in human medicine, agriculture, and animal husbandry accelerate this evolutionary process. Biofilm formation further complicates the issue, as bacteria within biofilms exhibit enhanced resistance due to limited drug penetration and altered metabolic states.^{26,27,42} The persistent and dynamic nature of resistance evolution poses a major challenge to the long-term effectiveness of antimicrobial therapies.

8.2 Safety and Toxicity Concerns

Safety and toxicity remain significant concerns in the development of new antimicrobial agents. While the primary goal is to eliminate pathogenic microorganisms, it is equally important to ensure minimal harm to the host. Many promising antimicrobial compounds fail during preclinical or clinical stages due to unacceptable toxicity profiles. Certain antimicrobial agents may exhibit cytotoxic effects, organ toxicity (such as nephrotoxicity or hepatotoxicity), or adverse immune reactions. For example, some drugs may disrupt mitochondrial function or interfere with host cellular processes due to similarities between microbial and human targets.^{33,25} Additionally, broad-spectrum antibiotics can disturb the normal microbiota, leading to complications such as secondary infections and dysbiosis.

Emerging therapies, including nanotechnology-based antimicrobials and antimicrobial peptides, also raise safety concerns.¹² Nanoparticles may accumulate in tissues and cause long-term toxicity, while peptides may trigger immune responses or undergo rapid degradation in the body. Ensuring the safety of these advanced therapies requires extensive evaluation, which increases development time and costs. Balancing efficacy

with safety is therefore a critical aspect of antimicrobial drug development, necessitating rigorous testing and monitoring throughout the drug development process.

8.3 Limited Clinical Data for New Therapies

Another major limitation is the lack of comprehensive clinical data for many newly developed antimicrobial therapies. While preclinical studies and early-phase clinical trials may demonstrate promising results, large-scale clinical validation is often lacking. This is particularly true for novel approaches such as phage therapy, CRISPR-based antimicrobials, and host-directed therapies.^{53,54} Clinical trials for antimicrobial agents face unique challenges, including difficulties in patient recruitment, variability in infection types, and ethical considerations. In many cases, infections caused by highly resistant pathogens are relatively rare or occur in critically ill patients, making it difficult to design standardized trials.^{53,54}

Moreover, regulatory requirements demand robust evidence of safety and efficacy, which can be challenging to obtain within limited timeframes. As a result, many new therapies receive conditional or accelerated approval based on limited datasets, necessitating post-marketing surveillance to monitor long-term outcomes. The lack of extensive clinical data also affects clinician confidence and adoption of new therapies. Without sufficient evidence, healthcare providers may be hesitant to replace established treatments with newer, less-proven alternatives.

8.4 Accessibility and Affordability Issues

Accessibility and affordability represent significant barriers to the effective implementation of new antimicrobial therapies, particularly in low- and middle-income countries.⁶¹ The high cost of drug development is often reflected in the pricing of newly approved antibiotics, making them inaccessible to large segments of the global population.

Pharmaceutical companies may prioritize markets with higher financial returns, leading to unequal distribution of new treatments. In many regions, limited healthcare infrastructure, inadequate diagnostic facilities, and lack of trained personnel further restrict access to advanced therapies. Antimicrobial stewardship programs, which aim to promote the rational use of antibiotics, may inadvertently limit the availability of new drugs to prevent the rapid emergence of resistance.⁶² While this approach is essential for preserving drug efficacy, it can reduce market demand and discourage investment in antibiotic development. Another concern is the availability of counterfeit or substandard drugs in certain regions, which can contribute to treatment failure and further resistance development. Ensuring equitable access to high-quality antimicrobial therapies requires coordinated efforts from governments, international organizations, and the pharmaceutical industry.

9 Future Perspectives

The growing threat of AMR demands forward-looking strategies that integrate scientific innovation, global cooperation, and responsible healthcare practices. While recent advances in antimicrobial drug development provide hope, long-term success will depend on addressing systemic challenges and adopting sustainable, multidisciplinary approaches. The future of combating AMR lies in coordinated global efforts, optimized antibiotic usage, personalized treatment strategies, and the integration of advanced technologies.

9.1. Need for Global Collaboration

AMR is a global health issue that transcends national boundaries, requiring coordinated international action. Pathogens do not recognize borders, and the spread of resistant organisms through travel, trade, and environmental pathways underscores the importance of global collaboration.⁶³ Effective management of AMR requires partnerships among governments, healthcare organizations, research institutions, and the pharmaceutical industry. Global initiatives should focus on strengthening surveillance systems to monitor resistance patterns, sharing data across countries, and developing standardized treatment guidelines.⁶⁴ Collaborative research programs can accelerate the discovery of novel antimicrobial agents and facilitate knowledge exchange. Funding mechanisms involving public-private partnerships are essential to support innovation in antibiotic development, especially given the limited commercial incentives for pharmaceutical companies. Efforts must also address disparities in healthcare infrastructure between developed and developing countries. Capacity building, training, and equitable resource allocation are necessary to ensure

that all regions can effectively respond to AMR. A unified “One Health” approach, integrating human, animal, and environmental health, is critical for controlling the spread of resistance globally.⁶⁴

9.2. Sustainable Antibiotic Use (Stewardship Programs)

The sustainability of antimicrobial therapies depends heavily on their rational and responsible use. Antibiotic stewardship programs play a crucial role in optimizing the use of antimicrobial agents to achieve the best clinical outcomes while minimizing the development of resistance.^{57,58} These programs involve coordinated interventions designed to promote appropriate prescribing, dosing, and duration of antibiotic therapy. In the future, stewardship efforts will need to expand beyond hospitals to include community healthcare settings, veterinary practices, and agriculture. Reducing unnecessary antibiotic prescriptions, especially for viral infections, is a key priority.⁵⁸ Education and awareness campaigns targeting healthcare professionals and the public are essential to promote responsible antibiotic use. Advanced diagnostic tools will further enhance stewardship programs by enabling rapid and accurate identification of pathogens, allowing for targeted therapy rather than empirical treatment. Policies regulating over-the-counter antibiotic sales and restricting their use in livestock for growth promotion will also contribute to sustainable use. Ultimately, stewardship programs must strike a balance between ensuring access to life-saving antibiotics and preserving their effectiveness for future generations.

9.3. Personalized Antimicrobial Therapy

Personalized antimicrobial therapy represents a promising future direction in the fight against AMR. Unlike conventional “one-size-fits-all” approaches, personalized therapy tailors treatment based on individual patient characteristics, pathogen profiles, and resistance patterns. This precision-based approach enhances treatment efficacy while minimizing unnecessary antibiotic exposure. Advances in genomics and molecular diagnostics have made it possible to rapidly identify pathogens and their resistance genes.⁶⁵ Whole-genome sequencing and metagenomic analysis can provide detailed insights into microbial communities and guide the selection of the most appropriate antimicrobial agents. Personalized dosing strategies, based on patient-specific factors such as age, weight, metabolism, and immune status, further optimize therapeutic outcomes. In addition, pharmacogenomics can help predict individual responses to antimicrobial drugs, reducing the risk of adverse effects and improving safety. Personalized therapy also has the potential to reduce the emergence of resistance by avoiding broad-spectrum antibiotic use when narrower, targeted options are available.⁶⁶ While challenges such as high costs and limited accessibility remain, continued advancements in diagnostic technologies and data analytics are expected to make personalized antimicrobial therapy more widely available in the future.

9.4. Integration of Advanced Technologies

The integration of advanced technologies is poised to revolutionize antimicrobial drug development and infection management.^{65,66} AI, machine learning, and big data analytics are already transforming the identification of novel drug candidates and predicting resistance patterns.^{14,51,52} These technologies enable rapid analysis of complex datasets, significantly accelerating the drug discovery process. Nanotechnology offers innovative solutions for targeted drug delivery, improving the efficacy and safety of antimicrobial agents.¹² Smart drug delivery systems can release drugs in response to specific environmental triggers, ensuring optimal therapeutic concentrations at infection sites while minimizing systemic exposure.

CRISPR-Cas gene-editing technology provides a powerful tool for precisely targeting and eliminating resistance genes in pathogens.⁶⁷ Similarly, synthetic biology approaches are being explored to engineer microorganisms capable of producing novel antimicrobial compounds. Digital health technologies, including wearable devices and remote monitoring systems, can enhance infection management by providing real-time data on patient health and treatment response. Integration of these technologies into healthcare systems will enable more proactive and efficient disease management. However, the adoption of advanced technologies also raises challenges related to cost, data security, regulatory approval, and ethical considerations. Addressing these issues will be essential to ensure their safe and effective implementation.

Conclusion

In conclusion, the rapid rise of AMR has necessitated a paradigm shift in antimicrobial drug development. This review highlights significant recent advances, including the development of novel antibiotics, antimicrobial peptides, phage therapy, nanotechnology-based systems, CRISPR-Cas approaches, and host-directed therapies. Additionally, strategies such as drug repurposing, combination therapy, and the integration of AI have contributed to accelerating drug discovery and improving therapeutic outcomes. These innovations collectively represent a move toward more targeted, efficient, and sustainable approaches to combating resistant pathogens.

In spite of these advancements, the challenge of AMR remains profound and continuously evolving. The emergence of MDR strains, safety concerns, limited clinical data, and issues related to accessibility and affordability underscore the complexity of the problem. Therefore, continued research is essential to refine existing therapies, discover new antimicrobial agents, and develop alternative treatment strategies. Investment in interdisciplinary research, along with strong collaboration between academia, industry, and healthcare systems, will be crucial in sustaining progress.

Most importantly, there is an urgent global need to combat AMR through coordinated efforts. Strengthening antimicrobial stewardship programs, improving surveillance systems, and promoting responsible use of antibiotics are key steps in preserving their effectiveness. International cooperation, guided by a One Health approach, is vital to address the interconnected nature of resistance across human, animal, and environmental health. In summary, while promising advances offer hope, sustained innovation, policy support, and global commitment are imperative to effectively tackle AMR and safeguard the future of infectious disease treatment.

References

- 1 Antabe R, Ziegler BR. Diseases, Emerging and Infectious. International Encyclopedia of Human Geography. 2020:389–91.
- 2 Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin Microbiol Rev. 2018 Aug 1;31(4):e00088-17
- 3 Alirol E, Getaz L, Stoll B, Chappuis F, Loutan L. Urbanisation and infectious diseases in a globalised world. Lancet Infect Dis. 2011 Feb;11(2):131-41.
- 4 Coque TM, Cantón R, Pérez-Cobas AE, Fernández-de-Bobadilla MD, Baquero F. Antimicrobial Resistance in the Global Health Network: Known Unknowns and Challenges for Efficient Responses in the 21st Century. Microorganisms. 2023 Apr 17;11(4):1050.
- 5 Caneschi A, Bardhi A, Barbarossa A, Zaghini A. The Use of Antibiotics and Antimicrobial Resistance in Veterinary Medicine, a Complex Phenomenon: A Narrative Review. Antibiotics (Basel). 2023 Mar 1;12(3):487.
- 6 Havers FP, Hicks LA, Chung JR, Gaglani M, Murthy K, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Flannery B, Fry AM. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018 Jun 1;1(2):e180243.
- 7 Enshaie E, Nigam S, Patel S, Rai V. Livestock Antibiotics Use and Antimicrobial Resistance. Antibiotics (Basel). 2025 Jun 19;14(6):621.
- 8 Li S, Liu J, Zhang X, Gu Q, Wu Y, Tao X, Tian T, Pan G, Chu M. The Potential Impact of Antibiotic Exposure on the Microbiome and Human Health. Microorganisms. 2025 Mar 5;13(3):602.
- 9 Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals (Basel). 2023 Nov 15;16(11):1615.
- 10 D'Andrea MM, Fraziano M, Thaller MC, Rossolini GM. The Urgent Need for Novel Antimicrobial Agents and Strategies to Fight Antibiotic Resistance. Antibiotics (Basel). 2019 Dec 6;8(4):254.
- 11 Niño-Vega GA, Ortiz-Ramírez JA, López-Romero E. Novel Antibacterial Approaches and Therapeutic Strategies. Antibiotics (Basel). 2025 Apr 15;14(4):404.

- 12 Fadaka AO, Sibuyi NRS, Madiehe AM, Meyer M. Nanotechnology-Based Delivery Systems for Antimicrobial Peptides. *Pharmaceutics*. 2021 Oct 26;13(11):1795.
- 13 Kundar R, Gokarn K. CRISPR-Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria. *Pharmaceuticals (Basel)*. 2022 Nov 30;15(12):1498.
- 14 Boudza R, Bounou S, Segura-Garcia J, Moukadiri I, Maicas S. Artificial Intelligence as a Catalyst for Antimicrobial Discovery: From Predictive Models to De Novo Design. *Microorganisms*. 2026 Feb 6;14(2):394.
- 15 Nusrat S, Aliyu M, Zohora FT. Mechanisms of antimicrobial resistance: From genetic evolution to clinical manifestations. *AIMS Microbiol*. 2025 Dec 18;11(4):1007-1034.
- 16 Bush K, Bradford PA. β -Lactams and β -Lactamase Inhibitors: An Overview. *Cold Spring Harb Perspect Med*. 2016 Aug 1;6(8):a025247.
- 17 Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. *Drug Resist Updat*. 2010 Dec;13(6):151-71.
- 18 Tomasz A. Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. *Rev Infect Dis*. 1986 Jul-Aug;8 Suppl 3:S260-78.
- 19 Fishovitz J, Hermoso JA, Chang M, Mobashery S. Penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*. *IUBMB Life*. 2014 Aug;66(8):572-7.
- 20 Jeremia L, Deprez BE, Dey D, Conn GL, Wuest WM. Ribosome-targeting antibiotics and resistance via ribosomal RNA methylation. *RSC Med Chem*. 2023 Mar 1;14(4):624-643.
- 21 Rafii F, Park M, Novak JS. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of *Clostridium perfringens* found after in vitro treatment with fluoroquinolones. *Antimicrob Agents Chemother*. 2005 Feb;49(2):488-92.
- 22 Nikaido H, Pagès JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. *FEMS Microbiol Rev*. 2012 Mar;36(2):340-63.
- 23 Gaurav A, Bakht P, Saini M, Pandey S, Pathania R. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. *Microbiology (Reading)*. 2023 May;169(5):001333.
- 24 Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. *Drugs*. 2009 Aug 20;69(12):1555-623.
- 25 Kim SW, Lee JS, Park SB, Lee AR, Jung JW, Chun JH, Lazarte JMS, Kim J, Seo JS, Kim JH, Song JW, Ha MW, Thompson KD, Lee CR, Jung M, Jung TS. The Importance of Porins and β -Lactamase in Outer Membrane Vesicles on the Hydrolysis of β -Lactam Antibiotics. *Int J Mol Sci*. 2020 Apr 17;21(8):2822.
- 26 Uruén C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. *Antibiotics (Basel)*. 2020 Dec 23;10(1):3.
- 27 Zhao A, Sun J, Liu Y. Understanding bacterial biofilms: From definition to treatment strategies. *Front Cell Infect Microbiol*. 2023 Apr 6;13:1137947.
- 28 Arnold BJ, Huang IT, Hanage WP. Horizontal gene transfer and adaptive evolution in bacteria. *Nat Rev Microbiol*. 2022 Apr;20(4):206-218.
- 29 Lopatkin AJ, Sysoeva TA, You L. Dissecting the effects of antibiotics on horizontal gene transfer: Analysis suggests a critical role of selection dynamics. *Bioessays*. 2016 Dec;38(12):1283-1292.
- 30 van Duin D, Paterson DL. Multidrug-Resistant Bacteria in the Community: An Update. *Infect Dis Clin North Am*. 2020 Dec;34(4):709-722.
- 31 Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. *Antimicrob Agents Chemother*. 1998 Dec;42(12):3251-5.
- 32 Marciano CL, Félix de Lima JV, Couto Rosa MSD, do Nascimento RA, Ferraz AO, Silva ICD, Chrysostomo-Massaró TN, Rosa-Garzon NGD, Cabral H. A Comprehensive Overview of Antimicrobial Peptides: Broad-Spectrum Activity, Computational Approaches, and Applications. *Antibiotics (Basel)*. 2025 Nov 5;14(11):1115.

- 33 Zhang QY, Yan ZB, Meng YM, Hong XY, Shao G, Ma JJ, Cheng XR, Liu J, Kang J, Fu CY. Antimicrobial peptides: mechanism of action, activity and clinical potential. *Mil Med Res*. 2021 Sep 9;8(1):48.
- 34 Hibstu Z, Belew H, Akelew Y, Mengist HM. Phage Therapy: A Different Approach to Fight Bacterial Infections. *Biologics*. 2022 Oct 6;16:173-186.
- 35 Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y, Tan XE, Veeranarayanan S, Thitiananpakorn K, Nguyen HM, Wannigama DL. A Comprehensive Review on Phage Therapy and Phage-Based Drug Development. *Antibiotics (Basel)*. 2024 Sep 11;13(9):870.
- 36 Georgakopoulou VE, Papalexis P, Trakas N. Nanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections. *J Biol Methods*. 2024 Oct 23;11(4):e99010032.
- 37 Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. *Int J Nanomedicine*. 2017 Feb 14;12:1227-1249.
- 38 Sharma A, Sharma V, Sharma S, Sharma S, Sharma M, Sivanesan I. Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance. *Pharmaceutics*. 2025 Nov 12;17(11):1459.
- 39 Ahmed MM, Kayode HH, Okesanya OJ, Ukoaka BM, Eshun G, Mourid MR, Adigun OA, Ogaya JB, Mohamed ZO, Lucero-Prisno DE 3rd. CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions. *Infect Drug Resist*. 2024 Nov 26;17:5229-5245.
- 40 Tao S, Chen H, Li N, Liang W. The Application of the CRISPR-Cas System in Antibiotic Resistance. *Infect Drug Resist*. 2022 Aug 2;15:4155-4168.
- 41 Ghazaei C. The role of bacteriophages and CRISPR-Cas in combating multidrug-resistant bacteria. *Nat Prod Bioprospect*. 2026 Jan 10;16(1):14.
- 42 Al-Madboly LA, Aboulmagd A, El-Salam MA, Kushkevych I, El-Morsi RM. Microbial enzymes as powerful natural anti-biofilm candidates. *Microb Cell Fact*. 2024 Dec 23;23(1):343.
- 43 Wilkinson D, Váchová L, Palková Z. Hostile Environments: Modifying Surfaces to Block Microbial Adhesion and Biofilm Formation. *Biomolecules*. 2025 May 23;15(6):754.
- 44 Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. *Nat Rev Drug Discov*. 2018 Jan;17(1):35-56.
- 45 Khatun S, Putta CL, Hak A, Rengan AK. Immunomodulatory nanosystems: An emerging strategy to combat viral infections. *Biomater Biosyst*. 2023 Jan 30;9:100073.
- 46 Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MAA. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. *Healthcare (Basel)*. 2023 Jul 5;11(13):1946.
- 47 Shareef U, Altaf A, Ahmed M, Akhtar N, Almuhayawi MS, Al Jaouni SK, Selim S, Abdelgawad MA, Nagshabandi MK. A comprehensive review of discovery and development of drugs discovered from 2020-2022. *Saudi Pharm J*. 2024 Jan;32(1):101913.
- 48 Song X. Antibacterial, Antifungal, and Antiviral Bioactive Compounds from Natural Products. *Molecules*. 2024 Feb 11;29(4):825.
- 49 Guo T, Sun X, Yang J, Yang L, Li M, Wang Y, Jiao H, Li G. Metformin reverse minocycline to inhibit minocycline-resistant *Acinetobacter baumannii* by destroy the outer membrane and enhance membrane potential in vitro. *BMC Microbiol*. 2022 Sep 12;22(1):215.
- 50 Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. *Trends Biotechnol*. 2013 Mar;31(3):177-84.
- 51 Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA, Tomietto G, Rapti C, Ruiz HK, Rawat S, Kumar D, Lalatsa A. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. *Pharmaceutics*. 2024 Oct 14;16(10):1328.
- 52 Elalouf A, Elalouf H, Rosenfeld A, Maoz H. Artificial intelligence in drug resistance management. *3 Biotech*. 2025 May;15(5):126.

- 53 Machado E, Sousa JC. New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria. *Antibiotics* (Basel). 2025 Oct 5;14(10):997.
- 54 Shou Y, Yeo JE, Pang AS, Paterson DL, Mo Y. Informed consent and risk communication challenges in antimicrobial clinical trials: a scoping review. *BMJ Open*. 2024 Nov 24;14(11):e082096.
- 55 Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. *BMJ*. 2020 Oct 7;371:m3434.
- 56 Gargate N, Laws M, Rahman KM. Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria. *NPJ Antimicrob Resist*. 2025 Jun 11;3(1):50.
- 57 Global action plan on antimicrobial resistance Jan 2026 <https://www.who.int/publications/i/item/9789241509763>
- 58 Antimicrobial Resistance Investments & Action Feb. 4, 2026 <https://www.cdc.gov/antimicrobial-resistance/programs/AR-investments.html>
- 59 GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance 8 July 2022 <https://gardp.org/gardp-and-carb-x-welcome-renewed-commitment-by-g7-leaders-to-address-antimicrobial-resistance/>
- 60 Niño-Vega GA, Ortiz-Ramírez JA, López-Romero E. Novel Antibacterial Approaches and Therapeutic Strategies. *Antibiotics* (Basel). 2025 Apr 15;14(4):404.
- 61 Naro SG, Palkovits M, Ruckert A, Caceres AM, Nagi R, Chik C, Hoffman SJ, Van Katwyk SR. A rapid scoping review of antibiotic access and use barriers among refugee and migrant populations. *Global Health*. 2026 Jan 29;22(1):20.
- 62 Rajendran R, Chitrapady S, Tejashree MU, Haritha K, Balakrishnan JM, Nair S, Karattuthodi MS, Khan S, Shalini S, Uday Kumar R, Vajid NV, Thunga G. Antimicrobial stewardship programs in primary and secondary care settings in India: current challenges, facilitators, perceptions, and impact - a scoping review. *BMC Infect Dis*. 2025 Nov 11;25(1):1539.
- 63 Cella E, Giovanetti M, Benedetti F, Scarpa F, Johnston C, Borsetti A, Ceccarelli G, Azarian T, Zella D, Ciccozzi M. Joining Forces against Antibiotic Resistance: The One Health Solution. *Pathogens*. 2023 Aug 23;12(9):1074.
- 64 Ajulo S, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. *PLoS One*. 2024 Feb 5;19(2):e0297921.
- 65 Alatawi AD, Hetta HF, Ali MAS, Ramadan YN, Alaqyli AB, Alansari WK, Aldaheri NH, Bin Selim TA, Merdad SA, Alharbi MO, Alatawi WAH, Algammal AM. Diagnostic Innovations to Combat Antibiotic Resistance in Critical Care: Tools for Targeted Therapy and Stewardship. *Diagnostics* (Basel). 2025 Sep 5;15(17):2244.
- 66 Morales-Durán N, León-Buitimea A, Morones-Ramírez JR. Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions. *Heliyon*. 2024 Mar 11;10(6):e27984.
- 67 Kundar R, Gokarn K. CRISPR-Cas System: A Tool to Eliminate Drug-Resistant Gram-Negative Bacteria. *Pharmaceuticals* (Basel). 2022 Nov 30;15(12):1498.